Below is a list of the companies that made news, or had unusually high volume on Friday, January 15, 2010.

Spansion Inc.
(Public, OTC:SPSNQ)

Spansion Inc. today announced operating results for its fourth quarter and fiscal year ended December 27, 2009. Spansion reported fourth quarter of 2009 net sales of $307.1 million and its second consecutive profitable quarter with net income on a U.S. GAAP basis of $4.3 million, or diluted net income per share of $0.02. Operating income for the quarter was $20.7 million and U.S. GAAP gross and operating margins were 33.1% and 6.7%, respectively.

Nanogen, Inc.
(Public, OTC:NGEN)

www.bharatbook.com included a new report on “Nanogen Inc Financial and Strategic Analysis Review” into its market report catalogue for reselling.

Nanogen, Inc. (Nanogen) is engaged in the development, manufacture and sale of advanced human invitro diagnostic products. Their product line consist of molecular testing platforms, analyte-specific reagents (ASR), point of care diagnostic tests and real time polymerase chain reaction (PCR) reagent products. The company principally operates the U.S., Canada, Mexico and Europe. It is headquartered in California, United States and employs 288 people.

Imaging3, Inc.
(Public, OTC:IMGG)

Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, conducted a Conference Call on Tuesday, January 12, 2010 at 1:00 Pacific Standard Time. During the call, CEO Dean Janes discussed the company’s recent response from the FDA. The announcement was followed by a question and answer session in which Mr. Janes took questions.

The audio recording of the conference call is now available on the company’s website, www.imaging3.com.

Nutra Pharma Corp.
(Public, OTC:NPHC)

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be presenting and exhibiting at the upcoming Accredited Members, Inc. Winter 2010 Small Cap/Micro Cap Investment Conference in Scottsdale, Arizona, and at The World MoneyShow in Orlando, Florida.

“This is an exciting time for Nutra Pharma as we continue to rollout our first drug products and begin generating our first significant revenues in the history of the Company,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “These conferences provide excellent opportunities to expand our presence within the investment community and share our unique and exciting growth story,” he concluded.

The Accredited Members, Inc. Winter 2010 Small Cap/Micro Cap Investment Conference, which is scheduled for February 1st to February 3rd 2010, will be hosted at the Four Seasons Resort in Scottsdale Arizona. The World MoneyShow is scheduled for February 3rd to February 6th 2010 and will be held at the Gaylord Palms Hotel and Convention Center in Orlando, Florida.

Quasar Aerospace Industries, Inc.
(Public, PINK:QASP)

Dean Bradley, the CEO of Quasar Aerospace Industries, Inc., is pleased to announce the closing of the first two of its acquisitions. The companies were acquired with a combination of cash and notes. Their identity will be disclosed in a future press release after they have had an opportunity to inform all of their customers and vendors of the change in control.

The Company has entered into an agreement with Tigerfish Aviation Pty. Ltd. Of Australia to form a joint venture by forming a US company tentatively to be named Tigerfish Aviation USA, Inc. The ownership of this company will be 70% QASP and 30% Tigerfish/Australia. QASP will make an initial investment in the US company of $5,000,000 to move forward the development of the Retractable Amphibious Pontoon Technology (RAPT). The CEO was in Germany the third week of December and met with individuals from ELAN-EDAG, a worldwide private engineering firm that is eager to join us in taking the RAPT to the next level.

Last but not least the company made a substantial donation to the Red Cross Disaster Relief Fund for the victims of the devastating earthquake in Haiti. The CEO personally matched the company’s donation. We urge all of our shareholders to consider helping the charity of their choice to whatever level they can comfortably afford.

Sinobiopharma, Inc.
(Public, OTC:SNBP)

Sinobiopharma Inc. (SNBP), which provides enhanced generic drugs like Teva Pharmaceuticals, Inc. (TEVA) or Taro Pharmaceuticals, Inc. (TAROF), saw its revenues jump 120% as it swung to a profit for its latest quarter.

Sinobiopharma Inc. (SNBP), a manufacturer and marketer of biopharmaceutical products in China, announced earnings of $1,073,550 for the three months ended November 30, 2009, compared to a net loss of $1,045,239 during the same period a year ago.

Revenues increased 120% to $2,137,471 and gross margins that improved 182% to 80% of sales, both of which were attributed to continuing growth in the sales of Cisatracurium Besylate. The drug now represents approximately 96% of the company’s total sales.

Operating expenses decreased 63% to $596,154 due to a decrease in stock-based compensation and a reduction in general and administrative expenses. However, research and development expenses rose to $189,396 from $33,015 a year ago.

As a result, net cash from operating activities rose $804,518 to $1,124,109 compared to $319,591 for the six months ended November 30, 2008 versus November 30, 2009.

Notably, Sinobiopharma is also actively enhancing internal controls in order to improve reporting standards. In October 2009, the company engaged Xinjie Mu, a certified public accountant with extensive experience in internal control and U.S. GAAP reporting compliance, as Chief Financial Officer. These efforts should help increase investor confidence.

————————————————————————————————————————-

Wall Street investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Market Tools section on the right, upper-hand side of the page.

[[T_F]]Data Leak Prevention – Data Security Solutions – Information Theft Protection, Detection and Prevention Software Productstracefusion_signature=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[[T_F]]

A young and savvy, yet experienced and accomplished investments mogul since ‘01; Michael has amassed a fortune as a private self investor. Recently starting his own successful blog and turning it in to a corporation — MIV Investments Inc., a company offering advice to thousands of people worldwide and attracting contracts from various reputable sources. His articles and publications have been linked to Forbes, CNN Money, Reuters, Bloomberg, and many other top worldwide mainstream media sources.